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between quality indicators and hard outcomes were tested using Cox 
regression adjusting for confounding, reporting hazard ratios (HR) 
with 95% confidence intervals.
Results: Lipid and albuminuria-lowering treatment status were asso-
ciated with a lower risk of the composite outcome (HR = 0.77 [0.67, 
0.88]; HR = 0.75 [0.59, 0.94]). Glucose-lowering treatment status 
was associated with a lower risk of the composite outcome only in 
patients with an elevated HbA1c level (HR = 0.72 [0.56, 0.93]). 
Blood pressure–lowering treatment status was not associated with a 
risk of the composite outcome. Treatment intensification with glu-
cose lowering but not with lipid-, blood pressure–, and albuminuria-
lowering drugs was also associated with a lower risk of the composite 
outcome (HR = 0.73 [0.60, 0.89]).
Conclusion: Treatment quality indicators measuring lipid- and albu-
minuria-lowering treatment status are valid quality measures because 
they predict a lower risk of cardiovascular events and mortality in 
patients with diabetes. The quality indicator measuring glucose-
lowering treatment status should only be used for restricted popula-
tions with elevated HbA1c levels. Intriguingly, the tested indicators 
measuring blood pressure–lowering treatment status and treatment 
intensification with lipid-, blood pressure–, and albuminuria-lower-
ing drugs did not predict patient outcomes. These results question 
whether all of the currently used and proposed treatment indicators 
are valid to judge health care and economics.
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Introduction: The identification of novel genes or cellular pathways 
that are involved in pancreatic β -cell function, and the development 
of reliable probes for the in vivo imaging of β cells are key challenges 
of the current diabetes treatment. Furthermore, the discovery and the 
validation of biomarkers that are predictive for the progression of 
glycemic deterioration and treatment response to current standard 
therapies or for the development of diabetic macro- and microvas-
cular complications will lead to more effective and safer treatment 
of diabetes by patient stratification in a personalized medicines 
approach of their treatment.
Patients (or Materials) and Methods: The 3 diabetes projects of 
the Innovative Medicines Initiative (IMI)—IMIDIA, SUMMIT, and 
DIRECT—are focusing on different stages of diabetes development. 
While the focus of IMIDIA is the function of the pancreatic β cell and 
its in vivo imaging, the key aspects of DIRECT and SUMMIT are the 
identification and validation of biomarkers predictive for progression 
of diabetes and treatment response, and for the development of late 
stage complications during disease progression. These 3 consortia 
form the IMI Diabetes Platform.
Results: In IMIDIA, launched on February 1, 2010, twelve aca-
demic institutions, 8 Pharma partners, and 1 small and medium-sized 
enterprise (SME) are working together to elucidate novel pathways 
that improve β -cell function and to identify diagnostic biomarkers 
for treatment monitoring in diabetes. The 5-year project addresses 
key bottlenecks in the development of β -cell–focused therapies. The 
DIRECT consortium consisting of 21 academic institutions and 4 
Pharma partners addresses the personalized medicines approach in 
type 2 diabetes patients. The focus of the consortium is the identifica-
tion of surrogate markers that can be used for patient stratification 
according to glycemic deterioration of patients at high risk for dia-
betes or early onset of diabetes and makers predictive for response to 
current standard therapies of type 2 diabetes. DIRECT was launched 
on February 1, 2012. In SUMMIT, the joint research of 19 academic 
institutions, 6 Pharma partners, and 1 SME addresses the urgent 
need for novel treatments of diabetic complications beyond glucose-
lowering therapies. The key aspect of the consortium is the identi-
fication and validation of surrogate markers for the development 
of micro- and macrovascular complications during progression of 
diabetes. The project was launched on November 1, 2009.
Conclusion: Each single participant cannot undertake this holistic 
approach of the IMI Diabetes Platform alone. The close collaboration 
between expert institutes for diabetes research and clinical devel-
opment is required to achieve the ambitious goals of the diabetes 
consortia.
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Introduction: Patients on antiplatelet therapy have a higher incidence 
of bleeding complications and reversal of antiplatelet drug effects is 
an important issue at trauma or emergency departments. For old 
and conventional anticoagulants, reversal strategies are established. 
However, there is no experience or recommendation how to antago-
nize the reversible and highly effective P2Y12-inhibitor ticagrelor 
and how to restore platelet function after ticagrelor dosing. The aim 
of the study was to describe an ex vivo model to reverse the effects 
of ticagrelor and to estimate the optimal quantity of platelet transfu-
sions required to normalize platelet aggregation.
Patients (or Materials) and Methods: To normalize platelet aggrega-
tion, increasing amounts of autologous platelet-rich plasma (PRP) 
were added ex vivo to hirudin-anticoagulated blood which was 
obtained 3 hours after the administration of ticagrelor, by spiking 
PRP into blood at ratios of 1:10, 1:5, and 1:3. Platelet aggrega-
tion was assessed by whole blood multiple electrode aggregometry 
(MEA; Multiplate®). For interpretation of aggregation, we defined 
a cutoff level of 40 A.U. as the lower limit of the range. Volunteers 
above this level were considered to exhibit normal platelet reactivity. 
Nonparametric tests were used and statistical comparisons were per-
formed with the Friedman ANOVA, and the Wilcoxon test for post 
hoc comparisons. A 2-tailed P value < 0.05 was considered significant.
Results: The strategy to reverse the effect of ticagrelor was tested 
in 20 healthy volunteers. A clear dose-response was obtained after 
spiking whole blood with increasing amounts of PRP. After addition 
of PRP at a ratio of 1:10, platelet aggregation increased to 31 ± 14 
A.U. When assuming that 1 apheresis platelet concentrate (200 mL) 
typically contains a minimum of 2 × 1011 platelets, the ratio of 
1:10 corresponds to 0.5 unit of apheresis platelet concentrates. A 
ratio of 1:5—equivalent to 1 unit of platelet concentrates—increased 
ADP induced platelet aggregation to 41±14 A.U. Platelet aggregation 
increased further to 48±18 A.U. following the addition of PRP at a 
ratio of 1:3, which corresponds to 1.5 units of platelet concentrates. 
All comparisons were significant at P < 0.01.
Conclusion: Platelets dose-dependently improve ex vivo platelet 
aggregation of subjects after a loading dose of 180 mg of ticagrelor. 
It is estimated that > 2 units of apheresis platelet concentrates will be 
necessary to completely restore baseline platelet aggregation in the 
majority of patients. Point-of-care platelet function tests may be suit-
able tools to verify this concept in emergency patients and to estimate 
the extent of the reversal and de-risk on an individual patient’s level.
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